Loading...
XKRX128940
Market cap2.31bUSD
Dec 24, Last price  
264,500.00KRW
1D
-0.75%
1Q
-18.87%
Jan 2017
-13.42%
IPO
250.92%
Name

Hanmi Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:128940 chart
P/E
22.94
P/S
2.25
EPS
11,532.22
Div Yield, %
0.54%
Shrs. gr., 5y
0.33%
Rev. gr., 5y
7.97%
Revenues
1.49t
+11.97%
337,380,097,000606,192,086,560674,005,086,850730,133,509,600761,279,849,4701,317,534,519,130882,724,835,490916,586,234,6101,015,962,250,1101,113,649,783,9901,075,853,605,0101,203,185,652,8101,331,546,600,1201,490,887,463,720
Net income
146.23b
+76.63%
-12,698,688,0001,291,575,00022,636,854,46043,933,275,56035,509,505,540154,443,350,26023,325,623,23060,434,211,77034,156,165,93052,109,663,31017,289,714,88067,025,376,13082,791,735,410146,231,157,740
CFO
216.54b
+33.44%
18,944,112,00061,303,899,48063,268,201,68085,991,520,620-32,819,709,300101,712,291,080412,965,176,320-62,905,201,16025,982,256,13012,446,620,380151,534,949,940201,923,207,360162,268,943,060216,537,615,372
Dividend
Jun 27, 2024250 KRW/sh
Earnings
Jan 31, 2025

Profile

Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanmi.co.kr/
IPO date
Jul 30, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,490,887,464
11.97%
1,331,546,600
10.67%
1,203,185,653
11.84%
Cost of revenue
1,102,108,119
1,000,944,214
929,840,826
Unusual Expense (Income)
NOPBT
388,779,345
330,602,386
273,344,826
NOPBT Margin
26.08%
24.83%
22.72%
Operating Taxes
28,600,596
19,454,334
22,218,297
Tax Rate
7.36%
5.88%
8.13%
NOPAT
360,178,749
311,148,051
251,126,530
Net income
146,231,158
76.63%
82,791,735
23.52%
67,025,376
287.66%
Dividends
(17,995,573)
(5,992,225)
(5,881,330)
Dividend yield
0.40%
0.16%
0.17%
Proceeds from repurchase of equity
(3,070,611)
(3,834,087)
(4,873,541)
BB yield
0.07%
0.10%
0.14%
Debt
Debt current
483,775,431
489,193,004
455,166,884
Long-term debt
98,479,941
274,030,768
366,722,000
Deferred revenue
1,033,095
8,457,582
10,839,672
Other long-term liabilities
3,569,810
(38,528,556)
(720)
Net debt
280,343,639
544,229,394
559,737,592
Cash flow
Cash from operating activities
216,537,615
162,268,943
201,923,207
CAPEX
(47,746,546)
(49,593,078)
(34,424,929)
Cash from investing activities
(183,472,198)
(181,408,084)
(43,388,835)
Cash from financing activities
(126,786,667)
(36,866,795)
(113,330,636)
FCF
421,697,053
378,974,098
330,151,691
Balance
Cash
254,155,699
236,736,418
211,734,352
Long term investments
47,756,034
(17,742,040)
50,416,940
Excess cash
227,367,360
152,417,048
201,992,010
Stockholders' equity
728,292,487
853,182,883
752,936,626
Invested Capital
1,451,346,550
1,519,567,199
1,466,898,739
ROIC
24.25%
20.84%
16.44%
ROCE
23.17%
19.28%
15.92%
EV
Common stock shares outstanding
12,691
12,704
12,719
Price
352,500.00
20.65%
292,156.82
5.85%
276,000.00
-24.69%
Market cap
4,473,697,350
20.54%
3,711,435,490
5.73%
3,510,421,644
-24.78%
EV
4,898,809,243
4,393,025,981
4,195,504,913
EBITDA
487,233,324
427,444,393
362,431,166
EV/EBITDA
10.05
10.28
11.58
Interest
28,508,409
22,647,122
16,576,803
Interest/NOPBT
7.33%
6.85%
6.06%